Andromeda in Early Negotiations with American Pharma Company

Israel's Clal Biotechnology Industries said its subsidiary Andromeda Biotech is in early talks to be sold to an American drug company for a price that could reach hundreds of millions of dollars. Andromeda signed a memorandum of understanding to be sold to the unnamed firm, according to Clal, which owns 96 percent of Andromeda. Read the full story

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments